Article Text
Editorial commentary
Natalizumab-induced PML: can the beast be tamed?
Statistics from Altmetric.com
Footnotes
-
Competing interests RH has received personal compensation for being on the advisory board of and/or as consultancy fees from Teva, Sanofi, Genzyme, Bayer/Schering, Merck-Serono, Biogen-Idec, Novartis, Behring CSL, Morphosys; research grant support from Teva, Bayer/Schering, Serono, Biogen-Idec, Novartis.
-
Provenance and peer review Commissioned; internally peer reviewed.